Generation Bio Co Total Assets
Generation Bio Co total assets. Based on the latest financial reports, Generation Bio Co (GBIO) holds total assets worth $121.90 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see GBIO market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Generation Bio Co (2018–2024)
Total assets of Generation Bio Co from 2018 to 2024. This chart illustrates how Generation Bio Co's total assets have evolved over time, based on quarterly financial data. See latest Generation Bio Co stock price today for real-time trading data and today's change.
Generation Bio Co - Asset Composition Analysis
Generation Bio Co Total Assets Breakdown (December 2024)
Generation Bio Co total assets breakdown as of December 2024. Generation Bio Co's total assets of $121.90 Million consist of 83.4% current assets and 16.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.0% |
| Accounts Receivable | $1.56 Million | 0.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Generation Bio Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Generation Bio Co's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Generation Bio Co's current assets represent 83.4% of total assets in 2024, a decrease from 92.1% in 2018.
- Cash Position: Cash and equivalents constituted 33.0% of total assets in 2024, up from 8.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.7% of total assets.
Generation Bio Co Competitors by Total Assets
Key competitors of Generation Bio Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Generation Bio Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.44 | 6.34 | 23.86 |
| Quick Ratio | 4.44 | 6.34 | 23.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $72.42 Million | $161.09 Million | $256.51 Million |
Generation Bio Co - Advanced Valuation Insights
This section examines the relationship between Generation Bio Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.71 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | -38.3% |
| Total Assets | $231.20 Million |
| Market Capitalization | $35.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Generation Bio Co's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Generation Bio Co's assets decreased by 38.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Generation Bio Co (2018–2024)
The table below shows the annual total assets of Generation Bio Co from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $231.20 Million | -38.31% |
| 2023-12-31 | $374.76 Million | -0.40% |
| 2022-12-31 | $376.26 Million | -21.08% |
| 2021-12-31 | $476.77 Million | +62.08% |
| 2020-12-31 | $294.15 Million | +598.04% |
| 2019-12-31 | $42.14 Million | -49.54% |
| 2018-12-31 | $83.52 Million | -- |
About Generation Bio Co
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise me… Read more